Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Phase IIb study of bimekizumab in ankylosing spondylitis meets primary objective

Dec. 15, 2017

FDA approves Xeljanz and Xeljanz XR for psoriatic arthritis

Dec. 15, 2017

Corbus Pharmaceuticals initiates phase III RESOLVE-1 trial testing anabasum

Dec. 15, 2017

FDA approves Pfizer's infliximab biosimilar Ixifi

Dec. 14, 2017

Phase III data show efficacy of LMWF-5A in severe knee osteoarthritis

Dec. 7, 2017

Glenmark Pharmaceuticals identifies new nuclear receptor ROR-gamma antagonists

Dec. 5, 2017

Taltz approved by FDA for psoriatic arthritis

Dec. 4, 2017

Biophytis cleared to begin SARA-INT trial of Sarconeos in Belgium

Dec. 4, 2017

ID Pharma submits CTN in Japan for DiscGenics' IDCT-001 clinical trial

Nov. 30, 2017

Etanercept biosimilar LBEC-0101 demonstrates equivalence to original

Nov. 24, 2017

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...